Pharma Testing Software, a next-generation, real-time, 25-module clinical trial platform sale

BREAKTHROUGH CLINICAL TECH — 25% FOR EUR 25M BEFORE GLOBAL SCALE-UP

PRE-MONEY VALUATION: EUR 100,000,000

A global life-science technology group is offering 25% equity for EUR 25 million to accelerate the worldwide commercialization of V3 Pharma Testing Software, a next-generation, real-time, 25-module clinical trial platform engineered to compress drug development timelines and radically reduce operational costs.

Developed with contributions from global leaders Astra, IBM, and Merck, V3 Pharma Testing Software replaces fragmented trial-management ecosystems with a unified engine that automates analytics, clinical operations, imaging, regulatory functions, supply chain, safety, and financial controls — all in real time.

Independent validation confirms the platform cuts clinical development time and cost by more than 30–35%, delivering multi-million-euro efficiency gains per program and enabling pharmaceutical companies to reach the market years faster. This positions V3 as one of the most disruptive, margin-expanding technologies available in modern drug development.

THE OFFER

•

Investment Amount: EUR 25,000,000

•

Equity Offered: 25%

•

Pre-Money Valuation: EUR 100,000,000

•

Post-Money Valuation: EUR 125,000,000

•

Use of Funds: EU / US / Asia expansion, enterprise sales execution, regulatory integration, SaaS scale-up, technical infrastructure, and cybersecurity enhancement.

WHY THIS OPPORTUNITY IS UNMATCHED

Unrivaled Integrated Platform

V3 Pharma Testing Software consolidates 25 clinical, analytical, operational, and regulatory modules into a single, real-time architecture. It eliminates the expensive, slow, error-prone patchwork of legacy systems that dominate today’s clinical trial environment.

Prime Moment in Market Evolution

The pharmaceutical industry is undergoing a rapid digitalization shift. Rising R&D expenditures, escalating clinical complexity, and regulatory pressure make integrated platforms not optional — but essential.

Superior SaaS Model

•

Zero client licensing fees

•

Zero client hardware or IT staff requirements

•

Revenue generated per patient / CRF

•

Highly scalable, recurring, high-margin global SaaS model

•

Single global database enabling seamless worldwide deployment

Enterprise Validation

The platform’s origins involve contributions from Astra, IBM, and Merck, establishing deep credibility, robust engineering lineage, and a clear path to enterprise adoption.

COMPANY OVERVIEW & GROWTH MOMENTUM

THE COMPANY

A confidential, multinational technology holding that owns the full IP, codebase, and commercialization rights to V3 Pharma Testing Software, structured for rapid growth, cross-border operations, and strategic scalability.

TECHNOLOGY ADVANTAGES

•

25 real-time modules covering the full clinical lifecycle

•

Fully automated data handling and process flow

•

Eliminates manual operations and fragmented systems

•

Single-database global operation with minimal overhead

•

Shortens time-to-market dramatically, unlocking significant value for pharma sponsors

GROWTH MOMENTUM

•

First-mover advantage: No competing system offers comparable functionality or integration depth.

•

Expansion readiness: Commercial launch in Europe, USA, and India.

•

Exceptional ROI for clients: Faster approvals, lower operational cost, and superior regulatory transparency.

•

Exit potential: Positioned for acquisition by top pharma companies, CROs, or global enterprise software firms seeking dominant clinical-tech platforms.

CONTACT

Valters Gencs — M&A Advisor info@gencs.eu WhatsApp / Telegram: +371 29265441 vgfintechadvisors.com | fintechadvisors.co.uk